Skip to main content

ADVERTISEMENT

Susan Jones-Miller, MD, MS

Original Contribution
05/11/2022
The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the investigational device exemption study. At present, real-world data are not available. The...
The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the investigational device exemption study. At present, real-world data are not available. The...
The Auryon 355-nm laser...
05/11/2022
Journal of Invasive Cardiology
Original Contribution
09/01/2021
We present our own experience with the Venovo venous stent in treating iliac vein compression (ILVC). In this retrospective cohort, we included consecutive patients treated with the Venovo venous stent for ILVC at our center. Stent deployment...
We present our own experience with the Venovo venous stent in treating iliac vein compression (ILVC). In this retrospective cohort, we included consecutive patients treated with the Venovo venous stent for ILVC at our center. Stent deployment...
We present our own experience...
09/01/2021
Journal of Invasive Cardiology
05/29/2012
Abstract: Background. Gender-related differences in long-term outcomes of patients receiving the Endeavor zotarolimus-eluting stent (ZES) (Medtronic) have not been well defined. In this study, we evaluate the differences between men (M) and...
Abstract: Background. Gender-related differences in long-term outcomes of patients receiving the Endeavor zotarolimus-eluting stent (ZES) (Medtronic) have not been well defined. In this study, we evaluate the differences between men (M) and...
Abstract: Background....
05/29/2012
Journal of Invasive Cardiology
Jetstream Atherectomy in Treating Femoropopliteal In-Stent Restenosis: Meta-Analysis of the JETSTREAM-ISR and JET-ISR Trials
Vascular Disease
07/31/2020
We present the results of a patient-level meta-analysis of the two currently completed and core-lab adjudicated prospective trials of the Jetstream atherectomy system (Boston Scientific) in femoropopliteal in-stent restenosis (FP-ISR) and...
We present the results of a patient-level meta-analysis of the two currently completed and core-lab adjudicated prospective trials of the Jetstream atherectomy system (Boston Scientific) in femoropopliteal in-stent restenosis (FP-ISR) and...
We present the results of a...
07/31/2020
Journal of Invasive Cardiology
04/24/2019
Our aim was to examine the role of the Flex Vessel Prep system (VentureMed Group), a dynamic, microincision, non-balloon based system, prior to PTA in reducing or limiting severe dissections.
Our aim was to examine the role of the Flex Vessel Prep system (VentureMed Group), a dynamic, microincision, non-balloon based system, prior to PTA in reducing or limiting severe dissections.
Our aim was to examine the role...
04/24/2019
Journal of Invasive Cardiology
Original Contribution
06/27/2018
We assess the safety and efficacy of arteriotomy closure with the intravascular FemoSeal vascular closure device compared with manual compression in patients undergoing diagnostic cardiac catheterization via the common femoral artery.
We assess the safety and efficacy of arteriotomy closure with the intravascular FemoSeal vascular closure device compared with manual compression in patients undergoing diagnostic cardiac catheterization via the common femoral artery.
We assess the safety and...
06/27/2018
Journal of Invasive Cardiology
Original Contribution
10/15/2018
We report on intraprocedural and up to 1-year outcomes on the safety of the Atlas Gold balloon (Bard) in iliofemoral venous interventions.
We report on intraprocedural and up to 1-year outcomes on the safety of the Atlas Gold balloon (Bard) in iliofemoral venous interventions.
We report on intraprocedural and...
10/15/2018
Journal of Invasive Cardiology
Brief Communication
06/17/2022
The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the EX-PAD-03 investigational device exemption study and the Auryon single-center experience...
The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the EX-PAD-03 investigational device exemption study and the Auryon single-center experience...
The Auryon 355-nm laser...
06/17/2022
Journal of Invasive Cardiology